Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals (Nasdaq: RIGL) said VEPPANU (vepdegestrant) is now available by prescription in the US for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after progression on at least one endocrine therapy line, per an FDA-authorized test. The drug is dosed 200 mg orally once daily and priced at $29,400 per 30-day supply.
How this was made
The 30-second read
Why it matters
The article discloses US prescription availability, dosing (200 mg once daily), and list pricing ($29,400 per 30-day supply), plus key safety warnings (QTc prolongation, embryo-fetal toxicity) and interaction cautions (strong CYP3A inhibitors/inducers).
Market read
For traders, this is a concrete commercialization milestone with label-specific launch details that can affect near-term valuation and momentum, but it lacks new clinical or financial metrics.
What to watch
Uptake may be constrained by QTc monitoring requirements, CYP3A interaction management, and high list price ($29,400/30-day), which can slow payer approvals and real-world adoption.
Background
Rigel is commercial-stage and positions VEPPANU as the first and only FDA-approved PROTAC for a defined ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer population after endocrine therapy progression.
Ticker impact
Rigel says VEPPANU (vepdegestrant) is now available by prescription in the US for ER+/HER2-, ESR1-mutated mBC after endocrine therapy progression.
Moderate positive bias for RIGL, with follow-through dependent on payer coverage and real-world prescription ramp.
This is a primary disclosure of launch timing, indication, dosing, and $29,400 per 30-day supply, which are actionable for commercial-stage biotech valuation. However, the article provides no new efficacy/label expansion beyond launch and no quantified sales ramp.
Market effects
Highlights PROTAC commercialization momentum in ER+/HER2- ESR1-mutated breast cancer, potentially supporting investor appetite for targeted protein degradation platforms.
US launch focus may shift near-term sentiment for US oncology specialty distribution and payer negotiation dynamics.
Global license context (Arvinas and Pfizer) suggests future ex-US expansion optionality, but this release is US availability only.
Counterpoint
Launch PR may already be anticipated; without new trial data or guidance, the stock reaction could fade as investors demand measurable prescription and reimbursement traction.
Key entities
- companyRigel Pharmaceuticals, Inc.
Announces US prescription availability of VEPPANU for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy progression.
- productVEPPANU (vepdegestrant)
FDA-approved oral PROTAC with dosing and pricing provided, including QTc prolongation and drug interaction warnings.
- partnerArvinas, Inc.
Named in an exclusive global license agreement with Rigel to develop, manufacture, and commercialize VEPPANU.
- partnerPfizer Inc.
Named in the same exclusive global license agreement with Rigel for VEPPANU.
